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Inhalation Pharmacokinetics of
1,3-Butadiene and 1,2-Epoxybutene-3 in
Rats and Mice
by Reinhold J. Laib,* Johannes G. Filser,t Reinhard
Kreiling,* Rao R. Vangala,* and H. M. Bolt*
Studies were conducted on inhalation pharmacokinetics of 1,3-butadiene and of its primary reactive
metabolic intermediate 1,2-epoxybutene-3 in rats (Sprague-Dawley) and mice (B6C3F,). Investigations of
inhalation pharmacokinetics of 1,3-butadiene revealed saturation kinetics of 1,3-butadiene metabolism in
both species. For rats and mice linear pharmacokinetics apply at exposure concentrations below 1000 ppm
1,3-butadiene; saturation of 1,3-butadiene metabolism is observed at atmospheric concentrations of about
2000 ppm. The estimated maximal metabolic elimination rates were 400 ,umole/hr/kg for mice and 200
,mole/hr/kg for rats. This shows that 1,3-butadiene is metabolized by mice at about twice the rate ofrats.
Investigations of inhalation pharmacokinetics of 1,2-epoxybutene-3 revealed major differences in metab-
olism of this compound between both species. No indication of saturation kinetics of 1,2-epoxybutene-3
metabolism could be observed in rats up to exposure concentrations of 5000 ppm, whereas in mice the
saturation ofepoxybutene metabolism became apparent at atmospheric concentrations of about 500 ppm.
The estimated maximal metabolic rate for 1,2-epoxybutene-3 was 350 ,umole/hr/kg in mice and > 2600
,umole/hr/kg in rats. When the animals are exposed to high concentrations of 1,3-butadiene,
1,2-epoxybutene-3 is exhaled by rats and mice. Forrats 1,2-epoxybutene-3 concentration in the gas phase of
the system reaches a plateau at about 4 ppm. For mice, 1,2-epoxybutene-3 concentration increases with
exposure time until, at about 10 ppm, signs of acute toxicity are observed. Under these conditions hepatic
nonprotein sulfhydryl compounds are virtually depleted in mice but not in rats. After exposure ofrats and
miceto(1,4-_4C)1,3-butadiene, covalentbindingof('4C)butadiene-derivedradioactivitycouldbedetected. In
both species, comparable amounts of radioactivity were associated with liver DNA. Covalent binding to
nucleoproteins wastwice as high inmicewhencomparedtorats, andthus itparalleledthehighermetabolic
rate for 1,3-butadiene in this species. We conclude, that in addition to the higher metabolism of 1,3-buta-
diene in mice, limited detoxification and thus accumulation of its primary reactive intermediate
1,2-epoxybutene-3 must be a major determinant for the higher susceptibility of mice to 1,3-butadiene-
induced carcinogenesis.
Introduction
Long-term inhalation studies with rats and mice have
demonstrated remarkable species differences in the car-
cinogenic potency of 1,3-butadiene. An inhalation carci-
nogenicity study in mice (B6C3F1) exposed to 625 ppm
and 1225 ppm 1,3-butadiene for 60 weeks (1) showed a
marked increase in the incidence of primary tumors
including lymphomas, hemangiosarcomas of the heart,
lungadenomas, and carcinomas. Inmale and female rats
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(Sprague-Dawley) exposed to 2000 ppm and 8000 ppm
1,3-butadiene for 110 weeks (2) there was also an in-
creased incidence of tumors, but the types of tumors
(e.g., mammary, thyroid follicular cell adenomas, uter-
ine) differed from those seen in mice. Furthermore, in
contrast to the study in rats that did not showmortality
secondary to neoplasia, the study in mice had to be
terminated after 60 weeks because offatal tumors that
reduced survival (1).
In microsomal incubates 1,3-butadiene is metabolized
in the presence of a NADPH-regenerating system by
cytochrome P-450 to its epoxide 1,2-epoxybutene-3
(3-5). Further metabolic transformation ofthe epoxide
intermediate by epoxide hydrolase and/or monooxy-
genase would lead to 3,4-epoxy-1,2-butanediol (via
3-butene-1,2-diol) and to diepoxybutane (4,6). 1,2-
Epoxybutene-3 is conjugated with glutathione (4) and
can be metabolized by glutathione-S-transferase (5).LAIB ET AL.
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FIGURE 1. Metabolism of 1,3-butadiene according to Malvoisin et al.
(6). The potential reactive intermediates, 1,2-epoxybutene-3 (I),
diepoxybutane (II), and3,4-epoxy-1,2-butane-diol (III)areframed.
Recently the formation of 1,2-epoxybutene-3 from
1,3-butadiene was demonstrated in organ homogenates
ofrats and mice (7). In addition, 1,2-epoxybutene-3 and
diepoxybutane could be characterized, by vacuum-line
cryogenic distillation, inthe blood ofrats and mice after
exposure of the animals to 14C-butadiene (8). Figure 1
shows the metabolism of 1,3-butadiene according to a
proposal by Malvoisin and Roberfroid (6).
Thepurposeofourstudieswastoinvestigate whether
the higher susceptibility ofmice to 1,3-butadiene (when
compared torats) was due to quantitative differences in
1,3-butadiene metabolism between these two species.
Therefore, comparative studies have been conducted in
rats (Sprague-Dawley) and mice (B6C3F1) oninhalation
pharmacokinetics of 1,3-butadiene and of its reactive
metabolic intermediate 1,2-epoxybutene-3. Further-
more, 1,3-butadiene-induced depletion of the hepatic
nonprotein sulfhydryl (NPSH) content and the covalent
binding of 14C-butadiene to liver nuclear proteins and
DNA were investigated in both species.
Methods
The methodological details of these investigations
have already been published (9-12). Thus, only a brief
summary is given here of the methods used.
Gas Uptake and Kinetic Studies
Male Sprague-Dawley rats (150-280 g) and male
B6C3F1 mice (25-30 g) were used for the experiments.
Usually two rats or eight mice were placed in a closed
6.4-L desiccator jar, equipped with an 02 supply and
135 g soda lime for CO2 absorption (Fig. 2, top). The
animals wereexposed toinitialconcentrations of1,3-bu-
tadiene and 1,2-epoxybutene-3 between about 10 ppm
and 5000 ppm. Concentration changes of the gaseous
compounds were measured by gas chromatography af-
ter injecting either 1,3-butadiene or 1,2-epoxybutene-3
intothesystemorafteradministeringthecompounds IP
tothe animals. In someexperimentsdiethyldithiocarba-
mate, a metabolic inhibitor of cytochrome P-450, was
administered IP at a single dose of 300 mg/kg body
weight.
Kineticparametersweredeterminedfromtheconcen-
tration time-courses thus obtained, based on a two-
compartment, open pharmacokinetic model that was
developedby Filserand Bolt(13,14). Thismodelimplies
aone-compartment description ofthe experimental ani-
mal. The gas phase in the desiccator with volume V1
represented compartment one (Cpl), the animals with
volume V2, compartment two (Cp2) (Fig. 2, bottom).
The full details of the analytical procedures and the
pharmacokinetic analysis have been presented else-
where (10,11,15,16).
Exhalation of 1,2-Epoxybutene-3
Six mice (B6C3F1) or two rats (Sprague-Dawley)
were placed in a 6.4-L desiccator system as described
above. The animals were exposed to 1,3-butadiene at
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FIGURE 2. Top: Exposure system for the study of inhalation phar-
macokinetics (13,14). (A) Oxygen inlet, (B) septum for injection of
volatile compounds and for gas sampling, (C) soda lime. Bottom:
PharmacokineticmodelwiththecompartmentsCpl (gasphase)and
CP2 (animals), the dividing theoretical interphase I and the rate
constants of the partial process of invasion (k12), exhalation (k2l),
and first-order metabolic elimination (kl).
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concentrations higher than 2000 ppm (2000-4000 ppm),
which ensured maximal metabolism of the gas to 1,2-
epoxybutene-3. Concentration changes of1,3-butadiene
and exhaled 1,2-epoxybutene-3 in the gas phase of the
system were monitored by gas chromatography. The
1,3-butadiene concentration in the system was main-
tained above 2000 ppm for up to 17 hr (11).
Exposure ofAnimals to 1,3-Butadiene and
Nonprotein Sulfhydryl Assay
Male B6C3F1 mice (30-35 g), male Sprague-Dawley
rats (180-200 g), and male Wistar rats (180-200 g) were
used. For each individual experiment, six mice or three
rats wereplaced in a6.4-L all-glass exposure systemand
were exposed for up to 15 hrto 1,3-butadiene concentra-
tions between 2000 to 3000 ppm (Vmax - conditions) to
ensure maximal metabolism to 1,2-epoxybutene-3. Con-
centration changes were measured by gas chromatog-
raphy. Control animals were also housed in closed all-
glass chambers, but they were not exposed to 1,3-
butadiene. After an exposure period of7 hr or 15 hr, the
animals were removed from the system and hepatic
nonprotein suflhydryl (NPSH) contents were deter-
mined according to Ellmann (17). The depletion of he-
paticNPSH content wasthenexpressedin% + SD ofthe
respective control values. The full experimental details
of this study have been presented (12).
Exposure ofAnimals to (1,4-14C)1,3-
Butadiene and Isolation of Nuclear Proteins
and DNA
Male B6C3F1 mice (30-35 g) and male Wistar rats
(200-220g) were exposed in a 6.4-L all-glass desiccator
to (1,4-1 C) 1,3-butadiene (specific radioactivity 11.2
mCi/mmole). For each individual experiment 24 mice or
4 rats were used. Concentration changes of
(14C)1,3-butadiene in the gas phase ofthe system were
monitored by gas chromatography. After an exposure
period of6.6hr(rats) or4hr(mice), morethan98% ofthe
radioactivity was taken up by the animals. Total radio-
activity uptake was 2.7 mCi per kilogram body weight
for both species. Liver nucleoproteins and DNA were
isolated from the purified nuclei (18) by hydroxylapatite
chromatography (19). Radioactivity ofthe samples was
determined by liquid scintillation counting and was re-
lated to protein or DNA content. The full experimental
details ofthis study have been presented elsewhere (9).
Results and Discussion
Inhalation Pharmacokinetics of
1,3-Butadiene
Starting from different initial concentrations between
100 and 5000 ppm, the time-dependent decline of 1,3-
butadiene in the exposure system, occupied by rats or
mice, was investigated (10,15). The decline curves ob-
served in these experiments for rats or mice (the time
ppm 1, 3 - butadiene
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FIGURE 3. Time course of 1,3-butadiene concentrations in the gas
phase of a closed 6.4-L desiccator jar chamber occupied by eight
B6C3F1 mice. Individual experiments with different initial 1,3-bu-
tadiene concentrations between 100 and 5000 ppm.
course of 1,3-butadiene concentrations are shown for
mice in Figure 3) become flatter at higher exposure
concentrations, indicating saturable metabolism of
1,3-butadiene in both species. Below concentrations of
about 1000ppm, the elimination of1,3-butadienebyrats
or mice can be described by a first-order process. At
higher atmospheric concentrations saturation kinetics
become apparent. Saturation of 1,3-butadiene metab-
olismisobservedinratsandmiceatatmosphericconcen-
trationsofabout2000ppm. Thepharmacokineticparam-
eters for distribution and metabolism of 1,3-butadiene
were determined from the concentration-decline curves
obtained (10,15) (Table 1). They show, in principle, that
1,3-butadiene is metabolized by mice at about twice the
rate of rats. In the lower concentration range, where
first-order metabolism applies, metabolic clearance per
kgbodyweightwas 7300mL/hrformiceand4500mL/hr
for rats. The estimated maximal metabolic elimination
rates were 400 ,umole/hr/kg for mice and 220 ,umole/hr/
kg for rats.
Figure 4 shows the metabolic elimination rates of
1,3-butadieneforratsandmice, calculated forconditions
ofexposure in an open (V1 -> co) exposure system (13).
Table 1. Pharmacokinetic parameters for distribution and
metabolism of 1,3-butadiene in mice and rats related to
1 kg body weight.a
Parameter Mouse Rat Dimension
k12V1 10,280 5,750 mL/hr
k2l 3.2 2.5 hr-1
Keq. 2.7 2.3
K.tb 1.0 0.5
kel 7.6 8.8 hr-1
Clt0tbc 7,300 4,500 mL/hr
Vmax 400 220 ,mole/hr/kg
aFor definition of parameters see text and Filser and Bolt (13).
bCalculated for VI -m. oo
cValid for linear range of metabolism (up to 1000 ppm for both
species).
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FIGURE 4. Metabolic elimination rates of B6C3Fj mice (0) and
Sprague-Dawley rats (0) dependent on atmospheric concentrations
of 1,3-butadiene.
Table 2. Rates of 1,3-butadiene metabolism under conditions
oftheexposure concentrations applied in two inhalation bioassays
with rats (2) and mice (1).
Exposure Amount
concentration, metabolized,
ppm ,umole/hr/kg
Rat, Sprague-Dawley 1000 140
(Hazleton Labora-
tories, Europe) 8000 220
Mouse, B6C3Fj (NTP 625 165
Bioassay Program)
1250 300
Up to ambient concentrations of about 1000 ppm, the
metabolic elimination of1,3-butadiene is proportional to
the exposure concentration inmice and rats. Above 1000
ppmthe saturation kinetics of1,3-butadiene metabolism
become apparent in both species. A comparison of the
metabolic elimination rates of both species at different
exposureconcentrationsrevealsthatthemetabolicelim-
ination rate of 1,3-butadiene in mice is about twice that
in rats, both under conditions oflow- and high-exposure
concentrations. Based on Figure 4, the actual rates of
1,3-butadiene metabolism in both species can be calcu-
lated for the exposure concentrations used in the two
long-term bioassays with rats (2) and mice (1). Such
values maybe derivedunderthe assumptionthat 1,3-bu-
tadiene metabolism in mice and rats remains constant
during chronic exposure. A comparison of the data
(Table2) shows thatundertheparticularbioassaycondi-
tions, mice metabolized only about 35% more 1,3-buta-
diene than rats.
Inhalation Pharmacokinetics of
1,2-Epoxybutene-3
Investigations of inhalation pharmacokinetics of
1,2-epoxybutene-3 revealed major differences in this
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FIGURE 5. Timecourseof1,2-epoxybutene-3concentrationsinthegas
phase of a closed 6.4-L desiccator jar chamber occupied by eight
B6C3F1 mice. Individual experiments with different initial
1,2-epoxybutene-3 concentrations between 100 and 2000 ppm.
Table 3. Pharmacokinetic parameters for distribution and
metabolism of inhaled 1,2-epoxybutene-3 in mice and rats
related to 1 kg body weight.a
Parameter Mouse Rat Dimension
k12V1 33,500 13,800 mL/hr
k2l 0.79 0.37 hr'
Keqa 42.5 37 -
K,,,tb 10.2 1.16
kel 2.3 11.5 hr-1
Cltotb,c 24,900 13,400 mL/hr
Metabolic
saturation 500 NO" ppm
aFor definition of parameters see text and Filser and Bolt (13).
bCalculated for -. oo.
cValid for linear range of metabolism.
dNot observed up to 5000 ppm.
compounds' metabolism between both species (11,16).
When mice were exposed in the closed desiccatorjar to
different initial concentrations of1,2-epoxybutene-3 be-
tween 100 and 2000 ppm, the decline curves showed a
clear saturation behavior of 1,2-epoxybutene-3 metab-
olism (11) (Fig. 5). At lower concentrations the elimina-
tion of 1,2-epoxybutene-3 is directly proportional to its
concentration in the gas phase ofthe system. At higher
1,2-epoxybutene-3 concentrations, the slopes ofthe con-
centration time curves decrease, and the saturation of
1,2-epoxybutene-3 metabolism becomes apparent. In
contrast to these data, only monoexponential decline
curves were observed whenratswere exposed to differ-
entinitial 1,2-epoxybutene-3 concentrations between 10
and 5000 ppm (16).
In rats no indication of the saturation kinetics of
1,2-epoxybutene-3 metabolism could be observed up to
exposure concentrations of 5000 ppm, whereas in mice
the saturation of 1,2-epoxybutene-3 metabolism be-
comes apparent at atmospheric concentrations near 500
ppm. The pharmacokinetic parameters for distribution
and metabolism of 1,2-epoxybutene-3 were determined
from the concentration decline curves obtained (11,16)
(Table 3). They show that in the lower concentration
dNel [pmol.h-1.kg-1] butadiene
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FIGURE 6. Metabolic elimination rates of B6C3F1 mice (0) and
Sprague-Dawley rats (0) depending on atmospheric concentrations
of 1,2-epoxybutene-3. Metabolic elimination ofepoxybutene in rats
is linearly depending on the atmospheric concentration ofthe com-
pound up to 5000 ppm.
range where first-order metabolism applies (up to about
500 ppm), 1,2-epoxybutene-3 is metabolized by mice at
higherratesthanrats (metabolicclearance perkilogram
body weight, mice: 24,900 mL/hr; rats: 13,400 mL/hr.
Under these conditions the steady-state concentration
of 1,2-epoxybutene-3 in the mouse was calculated to be
about 10 times that in the rat. The calculated maximal
metabolic rate for 1,2-epoxybutene-3 was 350 pumole/hr/
kginmiceand > 2600,umole/hr/kg inrats. Acomparison
ofthe metabolic elimination rates of 1,2-epoxybutene-3
in both species (calculated for conditions of exposure in
an open (V1 -> co) system) reveals (Fig. 6) that at lower
exposure concentrations mice show a higher metabolic
rate for 1,2-epoxybutene-3 than rats. The metabolic
elimination of inhaled 1,2-epoxybutene-3 in rats is lin-
early dependent on the atmospheric concentration, at
least up to exposure concentrations of about 5000 ppm,
whereas in mice the saturation of 1,2-epoxybutene-3
metabolism becomes apparent at about 500 ppm. There-
fore, with increasing exposure concentration the meta-
bolic capacity for 1,2-epoxybutene-3 becomes rate limit-
ing in mice, but not in rats.
Exhalation of 1,2-Epoxybutene-3
Exhalation of1,2-epoxybutene-3 into the atmosphere
ofthe closed exposure system is observed when mice or
rats are exposedto 1,3-butadiene (11,16). In both exper-
iments 1,3-butadiene concentrations were maintained
above 2000 ppm, which ensured that the metabolism of
1,3-butadiene proceeded under saturation conditions.
Remarkable differences are obvious between both spe-
cies (Fig. 7). 1,2-Epoxybutene-3 exhaled byrats reaches
a plateau concentration of about 4 ppm, whereas its
exhalationby mice leads to an increase inconcentration,
until apeak concentration ofabout 10 ppm inthe system
is reached after 10 hr. The subsequent decline in the
atmospheric epoxide concentration in the experiment
FIGURE 7. Decrease of hepatic NPSH content in butadiene-exposed
mice (0, B6C3F1) and rats A , Sprague-Dawley; o, Wistar); upon
exposure to 1,3-butadiene at concentrations (>2000ppm) that cause
maximal metabolism to 1,2-epoxybutene-3 forboth species. Percent
ofthe corresponding controls are shown. Values represent six mice
orthreerats + SD. Forcomparison the time courses areincluded of
1,2-epoxybutene-3 concentrations (EB)exhaledintothe gasphaseof
the closed exposure system (6.4-L) by two Sprague-Dawley rats (A)
or six B6C3F1 mice (0) under similar experimental conditions.
with mice is due to a decrease in 1,3-butadiene metabo-
lism. Fromabout 12 hronward, mice showsigns ofacute
toxicity, and lethality occurs when the 1,3-butadiene
exposure is prolonged over 15 hr. No toxicity was ob-
served in rats using the same protocol.
The differences in 1,2-epoxybutene-3 exhalation and
in the toxicity of 1,3-butadiene between mice and rats
can be easily explained by the differences in pharmaco-
kinetics. Since the metabolic elimination of 1,2-
epoxybutene-3 in mice is a saturable process, the con-
centration of 1,2-epoxybutene-3 metabolically gener-
ated from 1,3-butadiene gradually increases in the ani-
mal (under saturation conditions of 1,3-butadiene
metabolism). Because exhalation of a volatile compound
is proportional to its concentration in the animal, this
also results in an increase in 1,2-epoxybutene-3 concen-
tration in the atmosphere of the closed-exposure sys-
tem. The finaldeclinein 1,3-butadienemetabolismin the
mouse experiment (Fig. 7), which is associated with a
reduction in epoxide exhalation, can be attributed to a
toxic action of 1,2-epoxybutene-3. This is supported by
the fact that at the end ofthe 15-hr exposure period the
hepatic nonprotein sulfhydryl content is reduced to
about 4% ofthat ofnonexposed animals. Under similar
conditions of1,3-butadiene exposure in rats, the hepatic
nonproteinsulfhydrylcontentshows nomajordepletion.
Depletion of Hepatic Nonprotein Sulfhydryl
Content
After the inhalation exposure of mice (B6C3F1) and
rats (Sprague-Dawley, Wistar) remarkable species dif-
ferences in the extent and time course of depletion of
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ferences in the extent and time course of depletion of
livernonprotein sulfhydryl (NPSH) content are obvious
(Fig. 7). Exposure of mice to concentrations of >2000
ppm 1,3-butadiene resulted in a progressive depression
ofhepatic NPSH to avalue ofabout20% after 7hrand a
practically total depletion ofhepatic NPSH after 15 hr.
Inratsthehepatic NPSHcontent wasdepletedtovalues
between 65% (Wistar) and 80% (Sprague-Dawley) after
7 hr, but they showed no majorchanges when exposure
to 1,3-butadiene wascontinued for8hr. Attheendofthe
15-hr exposure to 1,3-butadiene, mice showed signs of
acute toxicity. Neither Wistar or Sprague-Dawley rats
showed signs of toxicity after a 15-hr exposure to
1,3-butadiene.
In addition to the higher production rate of epoxy-
butene from 1,3-butadiene in mice, metabolism of
1,2-epoxybutene-3 is saturable inmice (B6C3F1) but not
in rats (Sprague-Dawley). This leads, at high exposure
concentrationsof1,3-butadiene, to acontinuous accumu-
lationinmice of1,2-epoxybutene-3, which can be traced
in the exhaled air of the animals. A comparison of the
time course of hepatic NPSH depletion with the time
course of1,2-epoxybutene-3 concentrations intheclosed
system (Fig. 7), obtained under similar experimental
conditions, shows that both parameters are related to
each other. After an initial moderate decline in rats, the
hepatic NPSH levels show no major changes and the
1,2-epoxybutene-3 exhalation remained constant until
exposure to 1,3-butadiene was ended. For mice an in-
crease in 1,2-epoxybutene-3 exhalation can be observed
untilafterabout 10hrofexposure to 1,3-butadiene, then
the hepatic NPSH levels are depleted to about 10% of
their initial values. The subsequent reduction in
1,2-epoxybutene-3 exhalation by mice and the toxicity
observed when exposure to 1,3-butadiene is continued
can be attributed to this effect.
1,2-Epoxybutene-3 is conjugated with glutathione (4)
and canbemetabolized byglutathione-S-transferase (5).
Hepatic NPSH depletion by 1,3-butadiene may thus be
regarded as the combined result of spontaneous and
enzyme-mediated conjugation ofreactive 1,3-butadiene
intermediates with glutathione (20).
With regard to the chemical stability of reactive
1,3-butadiene intermediates (21) and theiraccumulation
in the mouse, (8,11), it seems reasonable to assume that
reductions of hepatic NPSH in mice may reflect the
situation in target organs like the lung and heart.
Alkylation of Nuclear Proteins and DNA
After exposure of mice (B6C3F1) or rats (Wistar) to
(14C)-butadiene, radioactivity was covalently bound to
liver nucleoprotein fractions and to total liver DNA of
both species (Fig. 8). This shows that reactive 1,3-
butadiene metabolites alkylate liver nucleoproteins and
DNA under conditions of exposure in vivo. Covalent
binding of radioactivity to liver nucleoproteins of mice
was about twice as high as in rats. This shows that, in
parallel to the higher metabolic rate ofbutadiene in the
mouse, the formation rate of reactive protein-binding
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FIGURE 8. Radioactivity in nucleoproteins and DNA of mouse
(B6C3F1) and rat (Wistar) liver after exposure of the animals to
(1,4-14C) 1,3-butadiene. (A) Early eluting nucleoproteins; (B) late
eluting nucleoproteins. Radioactivity uptake per kilogram body
weight was about 2.7 mCi for mice and rats.
metabolites is proportionally increased in this species.
Comparable amounts of (14C)-butadiene-derived radio-
activity were associated with the liver DNA of both
species, although 1,3-butadiene is metabolized in rats
andmiceatdifferentrates. Itisnotcleartowhichextent
the total radioactivity bound to liver DNA represents
DNA alkylation at specific DNA bases or the metabolic
incorporation into the physiological nucleosides. Re-
cently the formation in DNA of 7-(2-hydroxy-3-
buten-1-yl) guanine and of 7-(1-hydroxy-3-buten-2-yl)
guanine has been demonstrated after chemical reaction
of epoxybutene with DNA in vitro (22). Although this
supports the assumption that 1,2-epoxybutene-3, as the
major reactive intermediate, covalently binds to DNA,
we cannot rule out that diepoxybutane and/or 3,4-
epoxy-1,2-butanediol contribute to this effect. Further
data on the chemical nature and possible individual
differences of specific DNA adducts between rat and
mouse are necessary.
Conclusions
These investigations revealed that differences in spe-
cies susceptibility toinhaled 1,3-butadienebetween rats
and mice are related to differences in butadiene metab-
olism. We conclude that, in addition to the higher pro-
duction rate of1,2-epoxybutene-3 from 1,3-butadiene in
mice versus rats, limited detoxification and thus accu-
mulation ofthisprimaryreactive intermediate maybe a
major determinant for the higher susceptibility ofmice
to 1,3-butadiene-induced carcinogenesis.
This view is supported by observations that, under
exposure to high concentrations of1,3-butadiene, exha-
lationof1,2-epoxybutene-3 bymiceistwotothreetimes
thatofrats, hepatic NPSH contentisalmost.completely
depleted, and considerably higher blood levels of 1,2-
epoxybutene-3 (two to five times) and diepoxybutane
(up to three times) occur in mice (8).
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